US$ 23.89
stopping a glp 1 Weight loss maintenance after discontinuing GLP-1 : r/Zepbound The GLP-1 Exit Strategy: Evidence-Based
Description
Wegovy holds broader pediatric approval, while Zepbound offers OSA-specific indications

Ultimately, available evidence suggests that the long-term safety profile of GLP-1 receptor agonists remains favorable for most patients who tolerate therapy during the early stages of treatment
This multi-dimensional therapeutic potential is reshaping the positioning of GLP-1 drugs as comprehensive metabolic treatments rather than just glucose-lowering agents For instance, Novo Nordisks semaglutide is now marketed as Wegovy specifically for chronic weight management, while Eli Lillys tirzepatide has received FDA approval under the brand name Zepbound for obesity treatment, independent of diabetic status

The key is planning ahead so you can focus on enjoying your trip
A balanced discussion with your OB/GYN, pediatrician, and primary care provider should weigh the risks of delaying metabolic treatment against the theoretical risks of GLP-1 exposure during lactation

The segment of the Blue Cross market most vulnerable to the new policy are members enrolled in fully insured plans where insurers set the terms of coverage
:max_bytes(150000):strip_icc()/VWH-GettyImages-2275860768-a6f6e63304e048d0a829844c1dacbd8d.jpg)